Pfizer gets USFDA nod for potential blockbuster heart drug Tafamidis Medical Dialogues Bureau7 May 2019 9:45 AM ISTPfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under...
Pfizer quarterly profit in line, touts pipeline of future products Medical Dialogues Bureau31 Jan 2019 9:05 AM ISTOn a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would...
Pfizer says USFDA accepts regulatory submissions for review of tafamidis Medical Dialogues Bureau16 Jan 2019 9:35 AM ISTPfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial...
